Physician profile
Van Van
NPI 1457081770
$3,652.40
in general payments reported to CMS, 2019-2025
24 companies · $846 in 2025
The $846 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,947 · 2024: $859 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,543 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,542.91 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $464.93 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $417.55 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Abbvie INC. | $348.74 | 2023-2025 | |
| Alkermes, INC. | $268.99 | 2023 | Lybalvi, Aristada |
| Corium, LLC | $252.93 | 2023-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $237.79 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $227.49 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $156.38 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $142.33 | 2023-2025 | Rexulti |
| Mylan INC. | $124.97 | 2023 | Yupelri |
| Collegium Pharmaceutical, INC. | $124.79 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.17 | 2023-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $122.05 | 2023 | Qelbree |
| Neurocrine Biosciences, INC. | $117.92 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $108.49 | 2024 | Invega Sustenna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $106.74 | 2023-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $86.92 | 2023-2024 | Trintellix |
| Indivior INC. | $50.96 | 2023-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $39.12 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $38.11 | 2023 | Xelstrym, Secuado |
| Bioxcel Therapeutics, INC. | $36.17 | 2023 | Igalmi |
| Biogen, INC. | $25.02 | 2024 | |
| Neos Therapeutics, Lp | $17.05 | 2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $14.79 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.